RT Journal Article
SR Electronic
T1 Impact of the COVID-19 pandemic on routine surveillance for adults with chronic hepatitis B virus (HBV) infection in the UK
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.10.21265651
DO 10.1101/2021.11.10.21265651
A1 Campbell, Cori
A1 Wang, Tingyan
A1 Smith, David A
A1 Freeman, Oliver
A1 Noble, Theresa
A1 Várnai, Kinga A
A1 Harris, Steve
A1 Salih, Hizni
A1 Roadknight, Gail
A1 Little, Stephanie
A1 Glampson, Ben
A1 Mercuri, Luca
A1 Papadimitriou, Dimitri
A1 Jones, Christopher R
A1 Taylor, Vince
A1 Chaudhry, Afzal
A1 Phan, Hang
A1 Borca, Florina
A1 Olza, Josune
A1 Warricker, Frazer
A1 Romão, Luis
A1 Ramlakhan, David
A1 English, Louise
A1 Klenerman, Paul
A1 Andersson, Monique I.
A1 Collier, Jane
A1 Nastouli, Eleni
A1 Khakoo, Salim I
A1 Gelson, William
A1 Cooke, Graham S
A1 Woods, Kerrie
A1 Davies, Jim
A1 Barnes, Eleanor
A1 Matthews, Philippa C
YR 2021
UL http://medrxiv.org/content/early/2021/11/11/2021.11.10.21265651.abstract
AB Background and aims To determine the impact of the COVID-19 pandemic on the population with chronic Hepatitis B virus (HBV) infection under hospital follow-up in the UK, we quantified the coverage and frequency of measurements of biomarkers used for routine surveillance (ALT and HBV viral load).Methods We used anonymised electronic health record data from the National Institute for Health Research (NIHR) Health Informatics Collaborative (HIC) pipeline representing five UK NHS Trusts.Results We report significant reductions in surveillance of both biomarkers during the pandemic compared to pre-COVID years, both in terms of the proportion of patients who had ≥1 measurement annually, and the mean number of measurements per patient.Conclusions Further investigation is required to determine whether these disruptions will be associated with increased rates of adverse chronic HBV outcomes.Competing Interest StatementConflict of interest statement: GC reports personal fees from Gilead and Merck Sharp & Dohme outside the submitted work. BG reports other from Imperial National Institute for Health Research (NIHR) Biomedical Research Centres (BRC), during the conduct of the study. EN reports grants from ViiV healthcare, grants from GlaxoSmithKline (GSK), grants from Gilead, outside the submitted work. Other authors have no conflict of interest. Financial support statement: This work has been conducted using National Institute for Health Research (NIHR) Health Informatics Collaborative (HIC) data resources and funded by the NIHR HIC, and has been supported by NIHR Biomedical Research Centres at Cambridge, Imperial, Oxford, Southampton, and University College London Hospitals. GSC is an NIHR research professor, EB is an NIHR senior investigator. PCM is funded by the Wellcome Trust (ref. 110110/Z/15/Z) and holds an NIHR Senior Fellowship award. CC is a doctoral student who receives partial doctoral funding from GlaxoSmithKline (GSK). FW is an NIHR funded ACF. The views expressed in this letter are those of the authors and not necessarily those of the National Health Service, the NIHR, or the Department of Health. Funding StatementFinancial support statement: This work has been conducted using National Institute for Health Research (NIHR) Health Informatics Collaborative (HIC) data resources and funded by the NIHR HIC, and has been supported by NIHR Biomedical Research Centres at Cambridge, Imperial, Oxford, Southampton, and University College London Hospitals. GSC is an NIHR research professor, EB is an NIHR senior investigator. PCM is funded by the Wellcome Trust (ref. 110110/Z/15/Z) and holds an NIHR Senior Fellowship award. CC is a doctoral student who receives partial doctoral funding from GlaxoSmithKline (GSK). FW is an NIHR funded ACF. The views expressed in this letter are those of the authors and not necessarily those of the National Health Service, the NIHR, or the Department of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval: The research database for the NIHR HIC viral hepatitis theme was approved by South Central - Oxford C Research Ethics Committee (REF Number: 21/SC/0060). All methods in this study were carried out in accordance with relevant guidelines and regulations. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis study utilised routinely-collected individual-level secondary care data (including demographic and laboratory parameters) collected across NHS Trusts in England by the National Institute for Health Research (NIHR) Health Informatics Collaborative (HIC), as previously described (1,2). The NIHR Health Informatics Collaborative (HIC) is a partnership of 29 NHS trusts and health boards, including the 20 hosting NIHR Biomedical Research Centres (BRCs), working together to facilitate the equitable re-use of NHS data for translational research. The NIHR HIC has established cross-site data collaborations in areas such as cardiovascular medicine, critical care, renal disease, infectious diseases, and cancer. All data analysed in the present study are part of the NIHR HIC database.ALTAlanine transferaseCHBChronic HBVCOVID-19Coronavirus Disease 2019GHSSGlobal Health Sector StrategyHBVHepatitis B virusHCCHepatocellular carcinomaHICHealth Informatics CollaborativeNHSNational Health ServiceNIHRNational Institute for Health ResearchSARS-CoV-2Severe acute respiratory syndrome coronavirus 2VLViral loadWHOWorld Health Organization